Disc Medicine (IRON) Net Cash Flow (2020 - 2026)
Disc Medicine (IRON) posted quarterly Net Cash Flow of $9.8 million for Q2 2026, up 109.37% year-over-year from $4.7 million in Q2 2025, and up 537.41% quarter-over-quarter from -$2.2 million in Q1 2026.
Powered by 
Analysis
Disc Medicine (IRON) Net Cash Flow (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Net Cash Flow for 7 consecutive years, with $9.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow rose 109.37% year-over-year to $9.8 million; the TTM figure through Jun 2026 stood at -$28.7 million (up 81.31% YoY), while the FY2025 annual figure was -$101.3 million, up 39.69% from the prior year.
- Net Cash Flow grew to $9.8 million in Q2 2026 per IRON's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $141.1 million in Q2 2023 and bottomed at -$88.0 million in Q3 2024.
- Historically, Net Cash Flow has averaged $594722.2 across 5 years, with a median of -$8.1 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 1646.0% — and 2025, when it sank 24413.37%.
- Disc Medicine's Net Cash Flow stood at $139.1 million in 2022, then sank by 107.22% to -$10.0 million in 2023, then jumped by 97.99% to -$202000.0 in 2024, then tumbled by 24413.37% to -$49.5 million in 2025, then surged by 119.72% to $9.8 million in 2026.
- Business Quant data shows IRON's Net Cash Flow at $9.8 million in Q2 2026, -$2.2 million in Q1 2026, and -$49.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | 9.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.76 Mn |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -49.52 Mn |
| Sep 30, 2025 | 13.33 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | -69.76 Mn |
| Dec 31, 2024 | -202,000.00 |
| Sep 30, 2024 | -88.03 Mn |
| Jun 30, 2024 | -61.95 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Dec 31, 2023 | -10.04 Mn |
| Sep 30, 2023 | -7.06 Mn |
| Jun 30, 2023 | 141.12 Mn |
| Mar 31, 2023 | 41.81 Mn |
| Dec 31, 2022 | 139.14 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Jun 30, 2022 | -9.13 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Dec 31, 2021 | -83.24 Mn |
| Sep 30, 2021 | -17.35 Mn |